Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 9043
Country/Region: Uganda
Year: 2018
Main Partner: Henry M. Jackson Foundation for the Advancement of Military Medicine
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USDOD
Total Funding: $9,277,376 Additional Pipeline Funding: $1,781,283

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $777,463
Care: Orphans and Vulnerable Children (HKID) $1,349,878
Care: TB/HIV (HVTB) $550,628
Care: Pediatric Care and Support (PDCS) $322,331
Laboratory Infrastructure (HLAB) $183,816
Strategic Information (HVSI) $561,285
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $848,461
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Prevention: HIV Testing and Counseling (HVCT) $433,030
Sexual Prevention: Other Sexual Prevention (HVOP) $1,796,365
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $393,314
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $1,965,787
Treatment: Pediatric Treatment (PDTX) $95,018
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV_DSD 10-14, Female, Physical and/or Emotional Violence 2019 132
GEND_GBV_DSD 10-14, Female, Sexual Violence (Post-Rape Care) 2019 94
GEND_GBV_DSD 10-14, Male, Physical and/or Emotional Violence 2019 48
GEND_GBV_DSD 10-14, Male, Sexual Violence (Post-Rape Care) 2019 5
GEND_GBV_DSD 15-19, Female, Physical and/or Emotional Violence 2019 1,168
GEND_GBV_DSD 15-19, Female, Sexual Violence (Post-Rape Care) 2019 855
GEND_GBV_DSD 15-19, Male, Physical and/or Emotional Violence 2019 119
GEND_GBV_DSD 15-19, Male, Sexual Violence (Post-Rape Care) 2019 32
GEND_GBV_DSD 20-24, Female, Physical and/or Emotional Violence 2019 559
GEND_GBV_DSD 20-24, Female, Sexual Violence (Post-Rape Care) 2019 262
GEND_GBV_DSD 20-24, Male, Physical and/or Emotional Violence 2019 279
GEND_GBV_DSD 20-24, Male, Sexual Violence (Post-Rape Care) 2019 111
GEND_GBV_DSD 50+, Female, Physical and/or Emotional Violence 2019 145
GEND_GBV_DSD 50+, Female, Sexual Violence (Post-Rape Care) 2019 11
GEND_GBV_DSD 50+, Male, Physical and/or Emotional Violence 2019 89
GEND_GBV_DSD 50+, Male, Sexual Violence (Post-Rape Care) 2019 4
GEND_GBV_DSD <10, Female, Physical and/or Emotional Violence 2019 49
GEND_GBV_DSD <10, Female, Sexual Violence (Post-Rape Care) 2019 29
GEND_GBV_DSD <10, Male, Physical and/or Emotional Violence 2019 27
GEND_GBV_DSD <10, Male, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) 2019 450
GEND_GBV_DSD By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 3,777
GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) 2019 1,501
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence 2019 208
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care) 2019 19
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence 2019 143
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care) 2019 7
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence 2019 208
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care) 2019 19
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence 2019 143
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care) 2019 7
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence 2019 208
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care) 2019 19
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence 2019 143
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care) 2019 7
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence 2019 69
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care) 2019 7
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence 2019 47
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV_DSD Number of people receiving post-GBV care 2019 5,278
GEND_GBV_TA 15-19, Female, Physical and/or Emotional Violence 2019 6
GEND_GBV_TA 15-19, Female, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV_TA 20-24, Female, Physical and/or Emotional Violence 2019 1
GEND_GBV_TA 20-24, Male, Physical and/or Emotional Violence 2019 1
GEND_GBV_TA By PEP service provision (related to sexual violence services provided) 2019 1
GEND_GBV_TA By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 7
GEND_GBV_TA By type of service: Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV_TA Number of people receiving post-GBV care 2019 10
HTC_TST_DSD By Key Population: FSW, Negative 2019 3,134
HTC_TST_DSD By Key Population: FSW, Positive 2019 1,521
HTC_TST_DSD By Key Population: MSM, Negative 2019 206
HTC_TST_DSD By Key Population: MSM, Positive 2019 91
HTC_TST_DSD By Key Population: People in prisons and other enclosed settings, Negative 2019 7,218
HTC_TST_DSD By Key Population: People in prisons and other enclosed settings, Positive 2019 1,522
HTC_TST_DSD By Key Population: PWID, Negative 2019 10
HTC_TST_DSD By Key Population: PWID, Positive 2019 2
HTC_TST_DSD By Key Population: TG, Negative 2019 74
HTC_TST_DSD By Key Population: TG, Positive 2019 14
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative 2019 494
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive 2019 90
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative 2019 408
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive 2019 75
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative 2019 122
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive 2019 23
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative 2019 318
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive 2019 57
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative 2019 226
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive 2019 42
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative 2019 375
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive 2019 70
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative 2019 174
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive 2019 34
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative 2019 473
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive 2019 86
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative 2019 1,091
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive 2019 56
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative 2019 718
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive 2019 39
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative 2019 472
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive 2019 26
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative 2019 478
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive 2019 27
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative 2019 490
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive 2019 27
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative 2019 644
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive 2019 36
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative 2019 330
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive 2019 18
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative 2019 601
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive 2019 32
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative 2019 2,155
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive 2019 90
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative 2019 1,767
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive 2019 73
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative 2019 514
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive 2019 21
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative 2019 1,363
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive 2019 57
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative 2019 969
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive 2019 41
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative 2019 1,620
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive 2019 68
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative 2019 889
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive 2019 37
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative 2019 2,047
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive 2019 85
HTC_TST_DSD HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative 2019 634
HTC_TST_DSD HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive 2019 28
HTC_TST_DSD HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative 2019 508
HTC_TST_DSD HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive 2019 90
HTC_TST_DSD HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative 2019 418
HTC_TST_DSD HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive 2019 73
HTC_TST_DSD HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative 2019 121
HTC_TST_DSD HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive 2019 21
HTC_TST_DSD HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative 2019 322
HTC_TST_DSD HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive 2019 57
HTC_TST_DSD HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative 2019 228
HTC_TST_DSD HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive 2019 41
HTC_TST_DSD HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative 2019 383
HTC_TST_DSD HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive 2019 68
HTC_TST_DSD HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative 2019 209
HTC_TST_DSD HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive 2019 37
HTC_TST_DSD HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative 2019 482
HTC_TST_DSD HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive 2019 85
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative 2019 4,403
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive 2019 138
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative 2019 4,527
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive 2019 143
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative 2019 1,577
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive 2019 50
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative 2019 2,901
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive 2019 92
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative 2019 1,740
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive 2019 53
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative 2019 3,288
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive 2019 104
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative 2019 1,409
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive 2019 45
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative 2019 2,667
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive 2019 84
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative 2019 8,581
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive 2019 275
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative 2019 3,716
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive 2019 216
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative 2019 3,858
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive 2019 94
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative 2019 2,595
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive 2019 36
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative 2019 130
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive 2019 11
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative 2019 43
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive 2019 5
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative 2019 237
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive 2019 20
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative 2019 106
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive 2019 10
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative 2019 294
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive 2019 23
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative 2019 194
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive 2019 16
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative 2019 130
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive 2019 11
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative 2019 132
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive 2019 12
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative 2019 135
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive 2019 12
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative 2019 174
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive 2019 15
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative 2019 91
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive 2019 7
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative 2019 160
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive 2019 14
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative 2019 6
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive 2019 1
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative 2019 79
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive 2019 7
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative 2019 45
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive 2019 31
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative 2019 28
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive 2019 20
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative 2019 57
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive 2019 37
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative 2019 37
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive 2019 26
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative 2019 69
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive 2019 43
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative 2019 107
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive 2019 69
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative 2019 45
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive 2019 31
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative 2019 45
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive 2019 31
HTC_TST_DSD HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative 2019 10,746
HTC_TST_DSD HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive 2019 52
HTC_TST_DSD HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative 2019 1,433
HTC_TST_DSD HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive 2019 7
HTC_TST_DSD HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative 2019 1,433
HTC_TST_DSD HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive 2019 7
HTC_TST_DSD HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative 2019 1,433
HTC_TST_DSD HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive 2019 7
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 164,655
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 1-9, Negative 2019 570
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 1-9, Positive 2019 31
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 10-14, Female, Negative 2019 621
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 10-14, Female, Positive 2019 33
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 10-14, Male, Negative 2019 133
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 10-14, Male, Positive 2019 8
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 15-19, Female, Negative 2019 98
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 15-19, Female, Positive 2019 17
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 15-19, Male, Negative 2019 50
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 15-19, Male, Positive 2019 9
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 20-24, Female, Negative 2019 66
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 20-24, Female, Positive 2019 11
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 20-24, Male, Negative 2019 182
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 20-24, Male, Positive 2019 32
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 50+, Female, Negative 2019 2
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 50+, Male, Negative 2019 207
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 50+, Male, Positive 2019 37
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative 2019 417
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive 2019 17
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative 2019 208
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive 2019 9
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative 2019 278
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive 2019 11
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative 2019 772
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive 2019 32
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative 2019 6
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative 2019 874
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive 2019 37
HTC_TST_DSD Service Delivery Point (Facility) ANC: 15-19, Negative 2019 7,421
HTC_TST_DSD Service Delivery Point (Facility) ANC: 15-19, Positive 2019 242
HTC_TST_DSD Service Delivery Point (Facility) ANC: 20-24, Negative 2019 12,891
HTC_TST_DSD Service Delivery Point (Facility) ANC: 20-24, Positive 2019 418
HTC_TST_DSD Service Delivery Point (Facility) Index: 1-9, Negative 2019 432
HTC_TST_DSD Service Delivery Point (Facility) Index: 1-9, Positive 2019 25
HTC_TST_DSD Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 473
HTC_TST_DSD Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 26
HTC_TST_DSD Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 100
HTC_TST_DSD Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 7
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 97
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 19
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 49
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 9
HTC_TST_DSD Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 160
HTC_TST_DSD Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 31
HTC_TST_DSD Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 182
HTC_TST_DSD Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 35
HTC_TST_DSD Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 3
HTC_TST_DSD Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 140
HTC_TST_DSD Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 27
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 2,388
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 79
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 2,616
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2019 82
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 557
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2019 14
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 472
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 26
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 154
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 9
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 876
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 47
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 390
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 21
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 11
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 1
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 295
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 16
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 3,345
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 74
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 3,660
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 74
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 773
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 18
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 1,797
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 57
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 898
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 31
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 2,706
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 85
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 2,899
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 91
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 35
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 4
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 1,246
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 41
HTC_TST_DSD Service Delivery Point (Facility) Pediatric : <5 Negative 2019 5,180
HTC_TST_DSD Service Delivery Point (Facility) Pediatric : <5 Positive 2019 105
HTC_TST_DSD Service Delivery Point (Facility) TB: 1-9, Negative 2019 45
HTC_TST_DSD Service Delivery Point (Facility) TB: 1-9, Positive 2019 31
HTC_TST_DSD Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 20
HTC_TST_DSD Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 13
HTC_TST_DSD Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 10
HTC_TST_DSD Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 7
HTC_TST_DSD Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 65
HTC_TST_DSD Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 41
HTC_TST_DSD Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 97
HTC_TST_DSD Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 60
HTC_TST_DSD Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 107
HTC_TST_DSD Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 69
HTC_TST_DSD Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 45
HTC_TST_DSD Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 31
HTC_TST_DSD Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 28
HTC_TST_DSD Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 20
HTC_TST_DSD Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 65
HTC_TST_DSD Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 41
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 10-14, Negative 2019 1,790
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 10-14, Positive 2019 9
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 15-19, Negative 2019 8,954
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 15-19, Positive 2019 43
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 20-24, Negative 2019 8,954
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 20-24, Positive 2019 43
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 50+, Negative 2019 1,075
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 50+, Positive 2019 5
HTC_TST_TA By Key Population: FSW, Negative 2019 1,130
HTC_TST_TA By Key Population: FSW, Positive 2019 547
HTC_TST_TA By Key Population: MSM, Negative 2019 77
HTC_TST_TA By Key Population: MSM, Positive 2019 35
HTC_TST_TA By Key Population: People in prisons and other enclosed settings, Negative 2019 2,602
HTC_TST_TA By Key Population: People in prisons and other enclosed settings, Positive 2019 546
HTC_TST_TA By Key Population: TG, Negative 2019 28
HTC_TST_TA By Key Population: TG, Positive 2019 5
HTC_TST_TA HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative 2019 183
HTC_TST_TA HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive 2019 31
HTC_TST_TA HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative 2019 152
HTC_TST_TA HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive 2019 24
HTC_TST_TA HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative 2019 41
HTC_TST_TA HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive 2019 6
HTC_TST_TA HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative 2019 112
HTC_TST_TA HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive 2019 19
HTC_TST_TA HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative 2019 80
HTC_TST_TA HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive 2019 12
HTC_TST_TA HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative 2019 137
HTC_TST_TA HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive 2019 21
HTC_TST_TA HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative 2019 62
HTC_TST_TA HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive 2019 8
HTC_TST_TA HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative 2019 175
HTC_TST_TA HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive 2019 29
HTC_TST_TA HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative 2019 47
HTC_TST_TA HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive 2019 3
HTC_TST_TA HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative 2019 33
HTC_TST_TA HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive 2019 1
HTC_TST_TA HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative 2019 20
HTC_TST_TA HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative 2019 20
HTC_TST_TA HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative 2019 21
HTC_TST_TA HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative 2019 29
HTC_TST_TA HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative 2019 15
HTC_TST_TA HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative 2019 27
HTC_TST_TA HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative 2019 205
HTC_TST_TA HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive 2019 7
HTC_TST_TA HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative 2019 1,611
HTC_TST_TA HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive 2019 48
HTC_TST_TA HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative 2019 1,656
HTC_TST_TA HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive 2019 49
HTC_TST_TA HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative 2019 576
HTC_TST_TA HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive 2019 17
HTC_TST_TA HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative 2019 1,067
HTC_TST_TA HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive 2019 32
HTC_TST_TA HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative 2019 636
HTC_TST_TA HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive 2019 19
HTC_TST_TA HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative 2019 1,202
HTC_TST_TA HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive 2019 36
HTC_TST_TA HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative 2019 520
HTC_TST_TA HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive 2019 14
HTC_TST_TA HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative 2019 973
HTC_TST_TA HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive 2019 29
HTC_TST_TA HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative 2019 5,916
HTC_TST_TA HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive 2019 180
HTC_TST_TA HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative 2019 2,557
HTC_TST_TA HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive 2019 138
HTC_TST_TA HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative 2019 2,654
HTC_TST_TA HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive 2019 58
HTC_TST_TA HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative 2019 1,794
HTC_TST_TA HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive 2019 14
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative 2019 43
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive 2019 2
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative 2019 13
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative 2019 84
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive 2019 5
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative 2019 36
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive 2019 2
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative 2019 106
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive 2019 6
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative 2019 69
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive 2019 3
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative 2019 43
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive 2019 2
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative 2019 43
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive 2019 2
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative 2019 44
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive 2019 2
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative 2019 62
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive 2019 3
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative 2019 31
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive 2019 2
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative 2019 60
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive 2019 2
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative 2019 27
HTC_TST_TA HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive 2019 1
HTC_TST_TA HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative 2019 13
HTC_TST_TA HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive 2019 7
HTC_TST_TA HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative 2019 7
HTC_TST_TA HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive 2019 3
HTC_TST_TA HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative 2019 13
HTC_TST_TA HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive 2019 9
HTC_TST_TA HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative 2019 10
HTC_TST_TA HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive 2019 5
HTC_TST_TA HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative 2019 19
HTC_TST_TA HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive 2019 14
HTC_TST_TA HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative 2019 34
HTC_TST_TA HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive 2019 22
HTC_TST_TA HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative 2019 13
HTC_TST_TA HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive 2019 7
HTC_TST_TA HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative 2019 13
HTC_TST_TA HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive 2019 7
HTC_TST_TA HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Negative 2019 5,124
HTC_TST_TA HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Positive 2019 15
HTC_TST_TA HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Negative 2019 683
HTC_TST_TA HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Positive 2019 2
HTC_TST_TA HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Negative 2019 683
HTC_TST_TA HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Positive 2019 2
HTC_TST_TA HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Negative 2019 683
HTC_TST_TA HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Positive 2019 2
HTC_TST_TA Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 64,606
HTC_TST_TA Service Delivery Point (Facility) ANC: 15-19, Negative 2019 5,115
HTC_TST_TA Service Delivery Point (Facility) ANC: 15-19, Positive 2019 159
HTC_TST_TA Service Delivery Point (Facility) ANC: 20-24, Negative 2019 8,887
HTC_TST_TA Service Delivery Point (Facility) ANC: 20-24, Positive 2019 279
HTC_TST_TA Service Delivery Point (Facility) Index: 1-9, Negative 2019 139
HTC_TST_TA Service Delivery Point (Facility) Index: 1-9, Positive 2019 6
HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 149
HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 7
HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 33
HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 1
HTC_TST_TA Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 35
HTC_TST_TA Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 5
HTC_TST_TA Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 17
HTC_TST_TA Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 2
HTC_TST_TA Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 60
HTC_TST_TA Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 7
HTC_TST_TA Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 63
HTC_TST_TA Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 8
HTC_TST_TA Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 49
HTC_TST_TA Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 6
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 31
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 1
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 34
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2019 1
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 7
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 20
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 6
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 38
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 2
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 18
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 13
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 1,076
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 20
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 1,170
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 20
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 246
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 3
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 660
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 19
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 330
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 7
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 988
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 29
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 1,066
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 32
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 8
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 457
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 12
HTC_TST_TA Service Delivery Point (Facility) Pediatric : <5 Negative 2019 1,666
HTC_TST_TA Service Delivery Point (Facility) Pediatric : <5 Positive 2019 35
HTC_TST_TA Service Delivery Point (Facility) TB: 1-9, Negative 2019 13
HTC_TST_TA Service Delivery Point (Facility) TB: 1-9, Positive 2019 7
HTC_TST_TA Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 4
HTC_TST_TA Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 2
HTC_TST_TA Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 1
HTC_TST_TA Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 1
HTC_TST_TA Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 17
HTC_TST_TA Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 12
HTC_TST_TA Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 32
HTC_TST_TA Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 20
HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 34
HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 22
HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 13
HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 7
HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 7
HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 3
HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 17
HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 12
HTC_TST_TA Service Delivery Point (Facility) VMMC: 10-14, Negative 2019 855
HTC_TST_TA Service Delivery Point (Facility) VMMC: 10-14, Positive 2019 3
HTC_TST_TA Service Delivery Point (Facility) VMMC: 15-19, Negative 2019 4,272
HTC_TST_TA Service Delivery Point (Facility) VMMC: 15-19, Positive 2019 13
HTC_TST_TA Service Delivery Point (Facility) VMMC: 20-24, Negative 2019 4,272
HTC_TST_TA Service Delivery Point (Facility) VMMC: 20-24, Positive 2019 13
HTC_TST_TA Service Delivery Point (Facility) VMMC: 50+, Negative 2019 511
HTC_TST_TA Service Delivery Point (Facility) VMMC: 50+, Positive 2019 2
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted 2019 345
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted 2019 904
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted 2019 910
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted 2019 2,715
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted 2019 45
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted 2019 45
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted 2019 544
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted 2019 1,811
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted 2019 45
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted 2019 45
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted 2019 307
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted 2019 724
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted 2019 126
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted 2019 362
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted 2019 34
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted 2019 91
HTS_SELF_DSD HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner 2019 9,047
HTS_SELF_DSD HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted 2019 452
HTS_SELF_DSD HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted 2019 1,359
HTS_SELF_DSD HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted 2019 91
HTS_SELF_DSD HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted 2019 91
HTS_SELF_TA HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted 2019 91
HTS_SELF_TA HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted 2019 240
HTS_SELF_TA HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted 2019 241
HTS_SELF_TA HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted 2019 721
HTS_SELF_TA HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted 2019 11
HTS_SELF_TA HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Unassisted 2019 11
HTS_SELF_TA HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted 2019 144
HTS_SELF_TA HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted 2019 481
HTS_SELF_TA HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted 2019 11
HTS_SELF_TA HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted 2019 11
HTS_SELF_TA HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted 2019 81
HTS_SELF_TA HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted 2019 192
HTS_SELF_TA HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted 2019 34
HTS_SELF_TA HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted 2019 97
HTS_SELF_TA HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted 2019 10
HTS_SELF_TA HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted 2019 24
HTS_SELF_TA HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner 2019 2,406
HTS_SELF_TA HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted 2019 120
HTS_SELF_TA HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Unassisted 2019 360
HTS_SELF_TA HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Directly-Assisted 2019 24
HTS_SELF_TA HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Unassisted 2019 24
KP_PREV_DSD By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 13,173
KP_PREV_DSD By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 488
KP_PREV_DSD By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 8,096
KP_PREV_DSD By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 40
KP_PREV_DSD Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2019 21,797
OVC_SERV_DSD Age/Sex: 1-9 2019 5,810
OVC_SERV_DSD Age/Sex: 10-14 Female 2019 2,492
OVC_SERV_DSD Age/Sex: 10-14 Male 2019 2,281
OVC_SERV_DSD Age/Sex: 15-17 Female 2019 2,281
OVC_SERV_DSD Age/Sex: 15-17 Male 2019 1,865
OVC_SERV_DSD Age/Sex: <1 2019 830
OVC_SERV_DSD By: Age/sex: 18-24 Female 2019 2,285
OVC_SERV_DSD By: Age/sex: 25+ Female 2019 619
OVC_SERV_DSD By: Age/sex: Male 18-24 2019 1,864
OVC_SERV_DSD By: Age/sex: Male 25+ 2019 417
OVC_SERV_DSD Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2019 20,744
OVC_SERV_DSD OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Social Protection 942 OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner. 15,558 OVC_HIVSTAT_DSD Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2019 20,744
OVC_SERV_DSD OVC_SERV_N_DSD_Age_Sex_Service_v4 <1, Unknown Sex, Social Protection 2019 135
OVC_SERV_DSD Program Completion: Active 2019 19,709
OVC_SERV_DSD Program Completion: Graduation 2019 1,035
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17 2019 282
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24 2019 561
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+ 2019 1,963
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17 2019 225
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24 2019 450
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+ 2019 1,570
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14 2019 2,064
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17 2019 515
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14 2019 1,793
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17 2019 448
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14 2019 1,240
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17 2019 308
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14 2019 1,074
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17 2019 270
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14 2019 405
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17 2019 64
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14 2019 371
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17 2019 51
OVC_SERV_DSD Sum of Age/Sex disaggregates 2019 8,919
PMTCT_ART_DSD Already on ART at beginning of current pregnancy 2019 1,613
PMTCT_ART_DSD New on ART 2019 1,185
PMTCT_ART_DSD Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 2,798
PMTCT_ART_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 42,008
PMTCT_ART_TA Already on ART at beginning of current pregnancy 2019 1,140
PMTCT_ART_TA New on ART 2019 773
PMTCT_ART_TA Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 1,913
PMTCT_ART_TA Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 28,937
PMTCT_EID_DSD By infants who received a virologic test within 2 months of birth 2019 2,365
PMTCT_EID_DSD By infants who received their first virologic HIV test between 2 and 12 months of age 2019 433
PMTCT_EID_DSD Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 2,798
PMTCT_EID_DSD Sum of Infant Age disaggregates 2019 2,798
PMTCT_EID_TA By infants who received a virologic test within 2 months of birth 2019 1,599
PMTCT_EID_TA By infants who received their first virologic HIV test between 2 and 12 months of age 2019 314
PMTCT_EID_TA Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 1,913
PMTCT_EID_TA Sum of Infant Age disaggregates 2019 1,913
PMTCT_STAT_DSD By Age (Denominator): 20-24 2019 13,862
PMTCT_STAT_DSD By Age (Denominator): <15-19 2019 7,981
PMTCT_STAT_DSD By Age (Numerator): 15-19 2019 7,981
PMTCT_STAT_DSD By Age (Numerator): 20-24 2019 13,862
PMTCT_STAT_DSD By Number of known positives: 15-19 2019 10
PMTCT_STAT_DSD By Number of known positives: 20-24 2019 50
PMTCT_STAT_DSD By Number of new negative: 15-19 2019 7,729
PMTCT_STAT_DSD By Number of new negative: 20-24 2019 13,394
PMTCT_STAT_DSD By Number of new positives: 15-19 2019 242
PMTCT_STAT_DSD By Number of new positives: 20-24 2019 418
PMTCT_STAT_DSD Number of new ANC and L&D clients 2019 42,008
PMTCT_STAT_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 42,008
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 25-29, Female 2019 9,245
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 30-34, Female 2019 7,141
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 35-39, Female 2019 2,938
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 40-49, Female 2019 841
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 25-29, Female 2019 9,245
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 30-34, Female 2019 7,141
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 35-39, Female 2019 2,938
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 40-49, Female 2019 841
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive 2019 742
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative 2019 8,224
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive 2019 279
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive 2019 572
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative 2019 6,351
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive 2019 218
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive 2019 239
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative 2019 2,608
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive 2019 91
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive 2019 72
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative 2019 740
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive 2019 29
PMTCT_STAT_TA By Age (Denominator): 15-19 2019 5,498
PMTCT_STAT_TA By Age (Denominator): 20-24 2019 9,550
PMTCT_STAT_TA By Age (Numerator): 20-24 2019 9,550
PMTCT_STAT_TA By Age (Numerator): : 15-19 2019 5,498
PMTCT_STAT_TA By known positives: 15-19 2019 5
PMTCT_STAT_TA By known positives: 20-24 2019 33
PMTCT_STAT_TA By new negatives: 15-19 2019 5,334
PMTCT_STAT_TA By new negatives: 20-24 2019 9,238
PMTCT_STAT_TA By new positives: 15-19 2019 159
PMTCT_STAT_TA By new positives: 20-24 2019 279
PMTCT_STAT_TA Number of new ANC and L&D clients 2019 28,937
PMTCT_STAT_TA Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 28,937
PMTCT_STAT_TA PMTCT_STAT_D_TA_Age_Sex 25-29, Female 2019 6,363
PMTCT_STAT_TA PMTCT_STAT_D_TA_Age_Sex 30-34, Female 2019 4,920
PMTCT_STAT_TA PMTCT_STAT_D_TA_Age_Sex 35-39, Female 2019 2,029
PMTCT_STAT_TA PMTCT_STAT_D_TA_Age_Sex 40-49, Female 2019 577
PMTCT_STAT_TA PMTCT_STAT_N_TA_Age_Sex 25-29, Female 2019 6,363
PMTCT_STAT_TA PMTCT_STAT_N_TA_Age_Sex 30-34, Female 2019 4,920
PMTCT_STAT_TA PMTCT_STAT_N_TA_Age_Sex 35-39, Female 2019 2,029
PMTCT_STAT_TA PMTCT_STAT_N_TA_Age_Sex 40-49, Female 2019 577
PMTCT_STAT_TA PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive 2019 516
PMTCT_STAT_TA PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative 2019 5,662
PMTCT_STAT_TA PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive 2019 185
PMTCT_STAT_TA PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive 2019 402
PMTCT_STAT_TA PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative 2019 4,377
PMTCT_STAT_TA PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive 2019 141
PMTCT_STAT_TA PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive 2019 165
PMTCT_STAT_TA PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative 2019 1,807
PMTCT_STAT_TA PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive 2019 57
PMTCT_STAT_TA PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive 2019 46
PMTCT_STAT_TA PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative 2019 518
PMTCT_STAT_TA PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive 2019 13
PP_PREV_DSD Age/sex: 15-19 Female 2019 3,159
PP_PREV_DSD Age/sex: 15-19 Male 2019 883
PP_PREV_DSD Age/sex: 20-24 Female 2019 2,301
PP_PREV_DSD Age/sex: 20-24 Male 2019 1,674
PP_PREV_DSD Age/sex: 50+ Female 2019 299
PP_PREV_DSD Age/sex: 50+ Male 2019 525
PP_PREV_DSD Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2019 27,378
PP_PREV_DSD PP_PREV_N_DSD_Age_Sex_v2 25-29, Female 2019 1,936
PP_PREV_DSD PP_PREV_N_DSD_Age_Sex_v2 25-29, Male 2019 3,451
PP_PREV_DSD PP_PREV_N_DSD_Age_Sex_v2 30-34, Female 2019 1,931
PP_PREV_DSD PP_PREV_N_DSD_Age_Sex_v2 30-34, Male 2019 3,446
PP_PREV_DSD PP_PREV_N_DSD_Age_Sex_v2 35-39, Female 2019 1,135
PP_PREV_DSD PP_PREV_N_DSD_Age_Sex_v2 35-39, Male 2019 2,029
PP_PREV_DSD PP_PREV_N_DSD_Age_Sex_v2 40-49, Female 2019 1,657
PP_PREV_DSD PP_PREV_N_DSD_Age_Sex_v2 40-49, Male 2019 2,952
PP_PREV_DSD Sum of Age/Sex disaggregates 2019 8,841
PrEP_NEW_DSD Female 15-19 2019 103
PrEP_NEW_DSD Female 20-24 2019 394
PrEP_NEW_DSD Female 50+ 2019 17
PrEP_NEW_DSD FSW 2019 1,204
PrEP_NEW_DSD Male 15-19 2019 17
PrEP_NEW_DSD Male 20-24 2019 120
PrEP_NEW_DSD Male 50+ 2019 36
PrEP_NEW_DSD MSM 2019 67
PrEP_NEW_DSD Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 1,715
PrEP_NEW_DSD PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female 2019 173
PrEP_NEW_DSD PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male 2019 84
PrEP_NEW_DSD PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female 2019 173
PrEP_NEW_DSD PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male 2019 84
PrEP_NEW_DSD PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female 2019 173
PrEP_NEW_DSD PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male 2019 84
PrEP_NEW_DSD PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female 2019 173
PrEP_NEW_DSD PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male 2019 84
PrEP_NEW_DSD PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations 2019 11
PrEP_NEW_TA Female 15-19 2019 14
PrEP_NEW_TA Female 20-24 2019 46
PrEP_NEW_TA Female 50+ 2019 3
PrEP_NEW_TA FSW 2019 163
PrEP_NEW_TA Male 15-19 2019 3
PrEP_NEW_TA Male 20-24 2019 16
PrEP_NEW_TA Male 50+ 2019 5
PrEP_NEW_TA MSM 2019 9
PrEP_NEW_TA Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 231
PrEP_NEW_TA PrEP_NEW_N_TA_Age_Sex_v2 25-29, Female 2019 24
PrEP_NEW_TA PrEP_NEW_N_TA_Age_Sex_v2 25-29, Male 2019 12
PrEP_NEW_TA PrEP_NEW_N_TA_Age_Sex_v2 30-34, Female 2019 24
PrEP_NEW_TA PrEP_NEW_N_TA_Age_Sex_v2 30-34, Male 2019 12
PrEP_NEW_TA PrEP_NEW_N_TA_Age_Sex_v2 35-39, Female 2019 24
PrEP_NEW_TA PrEP_NEW_N_TA_Age_Sex_v2 35-39, Male 2019 12
PrEP_NEW_TA PrEP_NEW_N_TA_Age_Sex_v2 40-49, Female 2019 24
PrEP_NEW_TA PrEP_NEW_N_TA_Age_Sex_v2 40-49, Male 2019 12
PrEP_NEW_TA PrEP_NEW_N_TA_KeyPopAbr Other Key Populations 2019 1
TB_ART_DSD Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 315
TB_ART_DSD Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 54
TB_ART_DSD Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 536
TB_ART_DSD Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 50
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 955
TB_ART_TA Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 97
TB_ART_TA Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 14
TB_ART_TA Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 167
TB_ART_TA Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 13
TB_ART_TA The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 291
TB_PREV_DSD By Age/Sex (Denominator): 15+, Female 2019 5,103
TB_PREV_DSD By Age/Sex (Denominator): 15+, Male 2019 2,424
TB_PREV_DSD By Age/Sex (Denominator): <15, Female 2019 501
TB_PREV_DSD By Age/Sex (Denominator): <15, Male 2019 333
TB_PREV_DSD By Age/Sex (Numerator): 15+, Female 2019 4,337
TB_PREV_DSD By Age/Sex (Numerator): 15+, Male 2019 2,061
TB_PREV_DSD By Age/Sex (Numerator): <15, Female 2019 425
TB_PREV_DSD By Age/Sex (Numerator): <15, Male 2019 284
TB_PREV_DSD TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive 2019 7,271
TB_PREV_DSD TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive 2019 837
TB_PREV_DSD TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive 2019 218
TB_PREV_DSD TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive 2019 35
TB_PREV_DSD TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive 2019 6,178
TB_PREV_DSD TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive 2019 710
TB_PREV_DSD TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive 2019 188
TB_PREV_DSD TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive 2019 31
TB_PREV_DSD The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 7,107
TB_PREV_DSD The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 8,361
TB_PREV_TA By Age/Sex (Denominator): 15+, Female 2019 1,902
TB_PREV_TA By Age/Sex (Denominator): 15+, Male 2019 907
TB_PREV_TA By Age/Sex (Denominator): <15, Female 2019 187
TB_PREV_TA By Age/Sex (Denominator): <15, Male 2019 126
TB_PREV_TA By Age/Sex (Numerator): 15+, Female 2019 1,619
TB_PREV_TA By Age/Sex (Numerator): 15+, Male 2019 769
TB_PREV_TA By Age/Sex (Numerator): <15, Female 2019 160
TB_PREV_TA By Age/Sex (Numerator): <15, Male 2019 106
TB_PREV_TA TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive 2019 2,719
TB_PREV_TA TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive 2019 312
TB_PREV_TA TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive 2019 80
TB_PREV_TA TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive 2019 11
TB_PREV_TA TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive 2019 2,315
TB_PREV_TA TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive 2019 265
TB_PREV_TA TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive 2019 66
TB_PREV_TA TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive 2019 8
TB_PREV_TA The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 2,654
TB_PREV_TA The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 3,122
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 546
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 546
TB_STAT_DSD Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 91
TB_STAT_DSD Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 91
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1,107
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1,107
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 99
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 99
TB_STAT_DSD Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 1,843
TB_STAT_DSD Total number of registered new and relapsed TB cases, during the reporting period 2019 1,843
TB_STAT_TA Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 172
TB_STAT_TA Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 172
TB_STAT_TA Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 30
TB_STAT_TA Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 30
TB_STAT_TA Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 344
TB_STAT_TA Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 344
TB_STAT_TA Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 31
TB_STAT_TA Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 31
TB_STAT_TA Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 577
TB_STAT_TA Total number of registered new and relapsed TB cases, during the reporting period 2019 577
TX_CURR_DSD Age/Sex: 10-14 Female 2019 773
TX_CURR_DSD Age/Sex: 10-14 Male 2019 330
TX_CURR_DSD Age/Sex: 15-19 Female 2019 962
TX_CURR_DSD Age/Sex: 15-19 Male 2019 164
TX_CURR_DSD Age/Sex: 20-24 Female 2019 2,840
TX_CURR_DSD Age/Sex: 20-24 Male 2019 250
TX_CURR_DSD Age/Sex: 50+ Female 2019 5,107
TX_CURR_DSD Age/Sex: 50+ Male 2019 3,403
TX_CURR_DSD Age/Sex: <1 2019 155
TX_CURR_DSD Age/Sex: <1-9 2019 947
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2019 46,909
TX_CURR_DSD Sum of age/sex disaggregates 2019 1,126
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive 2019 4,054
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive 2019 714
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive 2019 5,800
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive 2019 1,702
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive 2019 4,738
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive 2019 2,221
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive 2019 6,971
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive 2019 5,778
TX_CURR_TA Age/Sex: 1-9 2019 347
TX_CURR_TA Age/Sex: 10-14 Female 2019 281
TX_CURR_TA Age/Sex: 10-14 Male 2019 121
TX_CURR_TA Age/Sex: 15-19 Female 2019 357
TX_CURR_TA Age/Sex: 15-19 Male 2019 59
TX_CURR_TA Age/Sex: 20-24 Female 2019 1,066
TX_CURR_TA Age/Sex: 20-24 Male 2019 89
TX_CURR_TA Age/Sex: 50+ Female 2019 1,910
TX_CURR_TA Age/Sex: 50+ Male 2019 1,273
TX_CURR_TA Age/Sex: <1 2019 55
TX_CURR_TA Number of adults and children receiving antiretroviral therapy (ART) 2019 17,530
TX_CURR_TA Sum of Age/Sex disaggregations 2019 416
TX_CURR_TA TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive 2019 1,519
TX_CURR_TA TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive 2019 267
TX_CURR_TA TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive 2019 2,168
TX_CURR_TA TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive 2019 635
TX_CURR_TA TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive 2019 1,773
TX_CURR_TA TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive 2019 832
TX_CURR_TA TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive 2019 2,620
TX_CURR_TA TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive 2019 2,158
TX_NEW_DSD Breastfeeding status 2019 477
TX_NEW_DSD By Age/Sex: 1-9 2019 200
TX_NEW_DSD By Age/Sex: 10-14 Female 2019 187
TX_NEW_DSD By Age/Sex: 10-14 Male 2019 49
TX_NEW_DSD By Age/Sex: 15-19 Female 2019 319
TX_NEW_DSD By Age/Sex: 15-19 Male 2019 104
TX_NEW_DSD By Age/Sex: 20-24 Female 2019 595
TX_NEW_DSD By Age/Sex: 20-24 Male 2019 267
TX_NEW_DSD By Age/Sex: 50+ Female 2019 15
TX_NEW_DSD By Age/Sex: 50+ Male 2019 197
TX_NEW_DSD By Age/Sex: <1 2019 34
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 5,239
TX_NEW_DSD Pregnancy status 2019 477
TX_NEW_DSD Sum of Age/Sex disaggregates 2019 1,733
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive 2019 738
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive 2019 486
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive 2019 319
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive 2019 325
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive 2019 333
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive 2019 437
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive 2019 227
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive 2019 407
TX_NEW_TA Breastfeeding status 2019 179
TX_NEW_TA By Age/Sex: 1-9 2019 69
TX_NEW_TA By Age/Sex: 10-14 Female 2019 63
TX_NEW_TA By Age/Sex: 10-14 Male 2019 15
TX_NEW_TA By Age/Sex: 15-19 Female 2019 120
TX_NEW_TA By Age/Sex: 15-19 Male 2019 37
TX_NEW_TA By Age/Sex: 20-24 Female 2019 218
TX_NEW_TA By Age/Sex: 20-24 Male 2019 94
TX_NEW_TA By Age/Sex: 50+ Female 2019 2
TX_NEW_TA By Age/Sex: 50+ Male 2019 72
TX_NEW_TA By Age/Sex: <1 2019 10
TX_NEW_TA Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 1,944
TX_NEW_TA Pregnancy status 2019 179
TX_NEW_TA Sum of Age/Sex disaggregates 2019 621
TX_NEW_TA TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive 2019 294
TX_NEW_TA TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive 2019 184
TX_NEW_TA TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive 2019 121
TX_NEW_TA TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive 2019 121
TX_NEW_TA TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive 2019 124
TX_NEW_TA TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive 2019 165
TX_NEW_TA TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive 2019 81
TX_NEW_TA TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive 2019 154
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 23,218
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 3,499
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 10,976
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 1,643
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 1,688
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 235
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 846
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 114
TX_PVLS_DSD Denominator: Indication: Routine 2019 36,728
TX_PVLS_DSD Denominator: Indication: Targeted 2019 5,491
TX_PVLS_DSD Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months. 2019 42,219
TX_PVLS_TA Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 8,678
TX_PVLS_TA Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 1,310
TX_PVLS_TA Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 4,103
TX_PVLS_TA Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 612
TX_PVLS_TA Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 631
TX_PVLS_TA Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 84
TX_PVLS_TA Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 314
TX_PVLS_TA Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 43
TX_PVLS_TA Denominator: Indication: Routine 2019 13,726
TX_PVLS_TA Denominator: Indication: Targeted 2019 2,049
TX_PVLS_TA Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 15,775
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 8,577
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 7,724
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 7,615
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 6,849
TX_RET_DSD Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 97
TX_RET_DSD Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 87
TX_RET_DSD Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 55
TX_RET_DSD Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 49
TX_RET_DSD Denominator by Status: Breastfeeding 2019 1,621
TX_RET_DSD Denominator by Status: Pregnant 2019 1,621
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 14,709
TX_RET_DSD Numerator by Status: Breastfeeding 2019 1,457
TX_RET_DSD Numerator by Status: Pregnant 2019 1,457
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 16,344
TX_RET_TA Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 3,056
TX_RET_TA Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 2,745
TX_RET_TA Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 2,702
TX_RET_TA Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 2,435
TX_RET_TA Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 32
TX_RET_TA Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 30
TX_RET_TA Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 15
TX_RET_TA Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 14
TX_RET_TA Denominator by Status: Breastfeeding 2019 574
TX_RET_TA Denominator by Status: Pregnant 2019 574
TX_RET_TA Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 5,224
TX_RET_TA Numerator by Status: Breastfeeding 2019 518
TX_RET_TA Numerator by Status: Pregnant 2019 518
TX_RET_TA Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 5,805
TX_TB_DSD Denominator: By Aggregated Age/Sex: <15, Female 2019 2,814
TX_TB_DSD Denominator: By Aggregated Age/Sex: <15, Male 2019 1,876
TX_TB_DSD Denominator: By Aggregated Age/Sex:15+, Female 2019 28,615
TX_TB_DSD Denominator: By Aggregated Age/Sex:15+, Male 2019 13,604
TX_TB_DSD Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 1,408
TX_TB_DSD Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2019 95
TX_TB_DSD Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 373
TX_TB_DSD Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 1,876
TX_TB_DSD Number of ART patients who were screened for TB at least once during the reporting period 2019 46,909
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive 2019 40,806
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive 2019 1,220
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive 2019 4,691
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive 2019 192
TX_TB_TA Denominator: By Aggregated Age/Sex: 15+, Female 2019 10,692
TX_TB_TA Denominator: By Aggregated Age/Sex: 15+, Male 2019 5,084
TX_TB_TA Denominator: By Aggregated Age/Sex: <15, Female 2019 1,053
TX_TB_TA Denominator: By Aggregated Age/Sex: <15, Male 2019 701
TX_TB_TA Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 525
TX_TB_TA Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2019 34
TX_TB_TA Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 142
TX_TB_TA Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 701
TX_TB_TA Number of ART patients who were screened for TB at least once during the reporting period 2019 17,530
TX_TB_TA TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive 2019 15,256
TX_TB_TA TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive 2019 455
TX_TB_TA TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive 2019 1,753
TX_TB_TA TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive 2019 66
VMMC_CIRC_DSD By Age: 10-14 2019 2,658
VMMC_CIRC_DSD By Age: 15-19 2019 13,289
VMMC_CIRC_DSD By Age: 20-24 2019 13,289
VMMC_CIRC_DSD By Age: 25-29 2019 15,937
VMMC_CIRC_DSD By Age: 50+ 2019 1,575
VMMC_CIRC_DSD By circumcision technique: Device-based VMMC 2019 350
VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 2019 52,776
VMMC_CIRC_DSD Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2019 53,126
VMMC_CIRC_DSD Sum of age disaggregates (FY15-Current) 2019 46,748
VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 2019 30,811
VMMC_CIRC_DSD VMMC_CIRC_N_DSD_Age_Sex 30-34, Male 2019 2,126
VMMC_CIRC_DSD VMMC_CIRC_N_DSD_Age_Sex 35-39, Male 2019 2,126
VMMC_CIRC_DSD VMMC_CIRC_N_DSD_Age_Sex 40-49, Male 2019 2,126
Cross Cutting Budget Categories and Known Amounts Total: $3,619,074
Gender: Gender Based Violence (GBV) $301,879
GBV Prevention
Key Populations: FSW $40,000
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Monitoring and evaluation of SW programs
Collection and use of strategic information on SWs and clients
Training of health workers and community outreach workers
Key Populations: MSM and TG $10,000
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Monitoring and evaluation of MSM/TG programs
Training of health workers and community outreach workers
Adolescent Girls and Young Women (AGYW) $1,373,195
Economic Strengthening $10,000
Human Resources for Health $110,000
Condoms: Policy, Tools, and Services $12,000
Water $100,000
Food and Nutrition: Policy, Tools, and Service Delivery $2,000
Construction $1,400,000
Motor Vehicles: Purchased $250,000
Food and Nutrition: Commodities $10,000